Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).
31 Janeiro 2024 - 9:42AM
Edgar (US Regulatory)
US Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
USA
Basel, January 31, 2024
Ladies and Gentlemen:
Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat
Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that
Novartis AG has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission on January 31, 2024.
Respectfully submitted,
Novartis AG
|
/s/ Karen L. Hale
|
|
/s/ Harry Kirsch
|
|
|
Karen L. Hale
Chief Legal Officer of Novartis
|
|
Harry Kirsch
Chief Financial Officer of Novartis
|
|
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
